Lab Results Comparison: Pre-Treatment vs. Post-Cycle 1
This comparison tracks key blood markers between October 17, 2025 (prior to starting treatment) and December 11, 2025 (following the first cycle of BR therapy).
Key Takeaway: The most notable change is the significant drop in Lymphocytes, which is the expected mechanism of the Rituximab targeting the B-cells. Kidney function has improved to normal levels, while Liver AST remains stable but slightly elevated.
1. Complete Blood Count (CBC)
| Marker | Oct 17 (Pre-Tx) | Dec 11 (Current) | Trend/Status |
|---|---|---|---|
| WBC (White Blood Cells) | 3.3 K/uL | 3.5 K/uL | Still Low |
| Lymphocytes (#) | 0.93 K/uL | 0.52 K/uL | Decreased (Expected) |
| Neutrophils (#) | 1.67 K/uL | 1.73 K/uL | Stable (Low) |
| Monocytes (%) | 12.5 % | 22.3 % | Increased |
| Platelets | 159 K/uL | 164 K/uL | Normal |
| Hemoglobin | 14.3 g/dL | 15.0 g/dL | Normal |
2. Metabolic & Organ Function
| Marker | Oct 17 (Pre-Tx) | Dec 11 (Current) | Trend/Status |
|---|---|---|---|
| BUN (Kidney) | 23 mg/dL (High) | 16 mg/dL | Normalized |
| eGFR (Kidney Function) | 84 mL/min (Low) | >90 mL/min | Normalized |
| AST (Liver) | 49 U/L (High) | 50 U/L | Stable (High) |
| LDH | Not Listed | 273 U/L | High |
- Lymphocytes: The decrease from 0.93 to 0.52 is a direct result of the immunotherapy.
- Kidney Health: Great news on the BUN and eGFR returning to optimal range.
- LDH: Currently at 273 U/L. This is a marker often tracked in lymphoma and will be monitored in future cycles.
The Narrative Comparison
[cite_start]Comparing the baseline lab results from October 17, 2025 [cite: 2][cite_start], against the latest post-treatment blood work from December 11, 2025[cite: 327], reveals how the first cycle of Bendamustine and Rituximab (BR) is impacting my system. The most distinct change is visible in the Complete Blood Count. [cite_start]While my overall White Blood Cell count (WBC) has remained relatively stable, hovering at a low 3.3 K/uL in October and 3.5 K/uL now[cite: 23, 376], the composition of those cells has shifted. [cite_start]Specifically, my absolute Lymphocyte count dropped significantly from 0.93 K/uL to 0.52 K/uL[cite: 20, 350]. This reduction is a hallmark of Rituximab therapy, which is designed to target and deplete B-lymphocytes. [cite_start]Meanwhile, my Neutrophils (the cells that fight bacterial infections) have remained stable, moving slightly from 1.67 K/uL to 1.73 K/uL [cite: 36, 511][cite_start], and my Platelets are holding steady in the normal range, currently at 164 K/uL[cite: 30, 439].
On the metabolic front, there is good news regarding kidney function. [cite_start]In October, my Urea Nitrogen (BUN) was elevated at 23 mg/dL, and my eGFR (filtration rate) was slightly low at 84 mL/min[cite: 54, 58]. [cite_start]The December results show a complete normalization of these markers, with BUN dropping to a healthy 16 mg/dL and eGFR rising to >90 mL/min[cite: 238, 274]. [cite_start]Liver function remains consistent with previous months; the AST enzyme is still slightly elevated at 50 U/L, virtually unchanged from the 49 U/L seen in October[cite: 49, 203]. [cite_start]A new marker tracked in this cycle is Lactate Dehydrogenase (LDH), which came in at 273 U/L[cite: 300], a value slightly above the reference range that will likely be monitored as a standard marker of cell turnover during lymphoma treatment.
No comments:
Post a Comment